

Quarterly Strategic Priorities Update

Since introducing AMCP's strategic priorities in the spring of 2021, AMCP and our members have provided quarterly updates to showcase our progress, efforts, and accomplishments in each defined focus area. So far, this includes developing and presenting events such as the Health Summit on Health Disparities and publishing proceedings from the Partnership Forum on digital therapeutics.

[Learn More](#)



Helping patients *START and STAY* on COSENTYX®

[Learn more ▶](#)



3/22 176366



Get Inspired by AMCP Nexus 2022 Keynote Sessions

From Dr. Leana Wen's Opening General Session on solutions to address racial disparities to Aimee Tharaldson's, PharmD, pipeline session on specialty pharmaceuticals in development, you are sure to gain helpful insights from Nexus 2022.

[Register Now](#)



Reducing Health Disparities: Exploring How Implicit Bias Influences Health Care

During AMCP 2022 in March, Dr. Kali Cyrus led a workshop titled: A Primer on Bias from Discovery to Implementing Strategies to Address. In this blog post, AMCP CEO, Susan Cantrell, explores key takeaways from this workshop and discusses how managed care professionals can implement Dr. Cyrus' strategies in their day-to-day.

[Learn More](#)



AMCP Board Approves New Where We Stand Statement

The AMCP Board of Directors approved a new Where We Stand statement on Addressing Racial and Health Disparities. The document describes AMCP's support for mitigating disparities and advancing conversations and activities that acknowledge that disparities exist.

[Learn More](#)

Committed to making sure your qualified commercially insured patients can *START and STAY* on COSENTYX®*

[Learn more ▶](#)



*Please see limitations, terms, and conditions at www.cosentyxhop.com/access-support.
3/22 176366

GUEST BLOG →



**Are We There Yet?
Incorporating Value
in Coverage Decisions**

by Jennifer Graff, PharmD



Are We There Yet? Incorporating Value in Coverage Decisions

En route to summer vacations across the country, parents are hearing that all-too-familiar question: “Are we there yet?” It’s also a question that many are asking in regards to our nation’s journey toward value-based care. In this guest blog post, Jennifer Graff, PharmD, discusses incorporating value in coverage decisions and how this applies to AMCP’s efforts in addressing value and access.

[Learn More](#)

**Now accepting
session proposals +
poster abstracts!**

Session Proposal Submission Deadline: Monday, Sept. 12
Poster Abstract Submission Deadline: Monday, Nov. 4

SUBMIT AT AMCPANNUAL.ORG



Now Accepting AMCP 2023 Poster Abstracts and Education Session Proposals

Now is your chance to present your innovative ideas to a vast audience of managed care pharmacy leaders. We are now accepting submissions for session proposals and poster abstracts for AMCP 2023!

[Learn More](#)



Access the New Lexicon for Value-Based Purchasing

The AMCP Value-Based Contracting Advisory Group released the value-based contracting white paper entitled Talking the Talk: In the World of Value-Based Care, Words Matter A Lexicon for Value-Based Purchasing. Without a common framework for dialogue and design of value-based purchasing, data challenges, regulatory barriers and lack of trust exacerbate the time to reach final contract negotiations and implementation of new payment models.

[Learn More](#)



AMCP Volunteer Spotlight: Marissa Schlaifer

AMCP’s volunteers are key players in propelling our mission forward. We appreciate the extra time each person dedicates to their position. To shed light on their amazing work, we are introducing the AMCP Volunteer Spotlight. In this installment, past AMCP Board President and current Optum VP of Policy, Marissa Schlaifer, shares her experience and why she chose to apply for the AMCP Board of Directors.

[Learn More](#)

Upcoming PIE Webinars

The following webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement:

- [Aug. 11](#): Fam-trastuzumab deruxtecan-nxki (T-DXd) in Low HER2-expressing Metastatic Breast Cancer
- [Aug. 17](#): Tucatinib in Colorectal Cancer: Pre-approval Information Exchange

AMCP
675 North Washington Street, Suite 220, Alexandria, VA 22314
703.684.2600 | www.amcp.org

Inquiries or submissions for publication should be directed to newsletter@amcp.org

Follow AMCP



[Manage My Emails](#)